US clinical-stage biotech firm, Mineralys Therapeutics, has announced that it has dosed the first patient as part of its trial investigating the treatment of lorundrostat for the treatment of uncontrolled hypertension (uHTN).The Launch-HTN trial (NCT06153693)is the second of two pivotal trials aimed at assessing the safety and efficacy of lorundrostat in combination with other background-prescribed treatments. The global, randomised, double-blinded, placebo-controlled Phase III trial plans to enrol approximately 1,000 eligible adult participants who are failing to achieve their blood pressure goal on two to five background antihypertensive medications. These subjects will then be randomised to one of three arms: placebo, lorundrostat 50 mg once daily (QD), or lorundrostat 50 mg QD and then titrated to 100 mg QD, as needed, at week six. Continue reading →

The program seeks to reduce the number of Black residents who have high blood pressure. Continue reading →

ROCKVILLE,Md. Continue reading →

High blood pressure, also known as hypertension, occurs when blood pushes against the walls of your arteries with excessive force. Its a widespread issue, literally affecting millions of individuals globally and nearly half of the U.S. Continue reading →

When it comes to exercise for heart health, you don't want to peak too early in life. Recent research suggests that if you want to protect yourself against high blood pressure as you age, you need to play the long game and keep your exercise levels up through middle age Continue reading →